Высокомощностная брахитерапия в монорежиме у пациентов с локализованным раком предстательной железы

Высокомощностная брахитерапия в монорежиме у пациентов с локализованным раком предстательной железы

Автор: Щукина Е.О., Бирюков В.А., Карякин О.Б., Иванов С.А.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Онкоурология

Статья в выпуске: 3 т.16, 2023 года.

Бесплатный доступ

Введение. Рак предстательной железы (РПЖ) является вторым по распространенности раком среди мужчин. В России число больных РПЖ в I-II стадии увеличилось с 47,7% в 2010г. до 60,7% в 2021г. Одним из основных методов лечения локализованного РПЖ является высокомощностная брахитерапия, которая на сегодняшний день обеспечивает высокую точность охвата дозой предстательной железы, одновременно минимизируя воздействие на рядом расположенные органы. В постоянно растущем объеме литературы высокомощностная брахитерапия рассматривается как метод безопасного и эффективного радикального лечения РПЖ.

Рак предстательной железы, брахитерапия, высокомощностная брахитерапия, сравнение режимов, брахитерапия в монорежиме

Короткий адрес: https://sciup.org/142240010

IDR: 142240010   |   DOI: 10.29188/2222-8543-2023-16-3-136-145

Список литературы Высокомощностная брахитерапия в монорежиме у пациентов с локализованным раком предстательной железы

  • The Global Cancer Observatory. Estimated number of new cases in 2020. Cancer Today 2021. [Electronic resource]. URL: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5 D=17&group_cancer=1&include_nmsc=0&include_nmsc_other=1.
  • Nguyen AT, Liu CS, Kamrava M. A «scoping» review of prostate brachytherapy and immune responses. Brachytherapy 2023;22(1):21–9. https://doi.org/10.1016/j.brachy.2022.10.009.
  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.
  • Каприн А.Д., Старинский В.В, Шахзадова А.О. Состояние онкологической помощи населению России в 2021 году. М., 2022; 239 с. [Kaprin A.D., Starinsky V.V., Shakhzadovа A.O. The state of oncological care for the population of Russia in 2021. M., 2022; 239 p. (In Russian)].
  • Каприн А.Д., Бирюков В.А., Черниченко А.В. и др. Брахитерапия рака предстательной железы. Опыт работы филиалов Национального медицинского исследовательского центра радиологии. Онкоурология 2018;14(1):94–9. [Kaprin A.D., Biryukov V.A., Chernichenko A.V. et al. Prostate cancer brachytherapy. Experience of the branches of the National Medical Research Center of Radiology. Onkourologiya = Cancer Urology 2018;14(1):94–9. (In Russian)]. https://doi.org/10.17650/1726-9776-2018-14-1-94-99.
  • А.С. Павлов. Внутритканевая гамма- и бетатерапия злокачественных опухолей. М.: Медицина 1967; 283 с. [A.S. Pavlov. Interstitial gamma and beta therapy of malignant tumors. M.: Medicine 1967; 283 p. (In Russian)].
  • Garzotto M, Fair WR. Historical perspective on prostate brachytherapy. J Endourol 2000;14(4):315-8. https://doi.org/10.1089/end.2000.14.315.
  • Lederman M. The early history of radiotherapy: 1895–1939. Int J Radiat Oncol Biol Phys 1981;7(5):639-48. https://doi.org/10.1016/0360-3016(81)90379-5.
  • Young HH. The use of radium and the punch operation in desperate cases of enlarged prostate. Ann Surg 1917;65(5):633-41.
  • Deming CL. Results in one hundred cases of cancer of prostate and seminal vesicles treated with radium. Surg Gynecol Obstet 1922;34:99-118.
  • Zaorsky NG, Davis BJ, Nguyen PL, Showalter TN, Hoskin PJ, Yoshioka Y, et al. The evolution of brachytherapy for prostate cancer. Nat Rev Urol 2017;14(7):415-39. https://doi.org/10.1038/nrurol.2017.76.
  • Flocks RH, Kerr HD, Elkins HB, Culp D. Treatment of carcinoma of the prostate by interstitial radiation with radio-active gold (Au 198): a preliminary report. J Urol 1952;68(2):510-22. https://doi.org/10.1016/S0022-5347(17)68230-2.
  • Whitmore WF Jr, Hilaris B, Grabstald H. Retropubic implantation to iodine 125 in the treatment prostatic cancer. J Urol 1972;108(6):918–20. https://doi.org/10.1016/s0022-5347(17)60906-6.
  • Hilaris BS, Whitmore WF Jr., Batata MA, Grabstald H. Radiation therapy and pelvic node dissection in the management of cancer of the prostate. Am J Roentgenol Radium Ther Nucl Med 1974;121(4):832–8. https://doi.org/10.2214/ajr.121.4.832.
  • Mate TP, Gottesman JE, Hatton J, Gribble M, Van Hollebeke L. High dose-rate afterloading 192 Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys 1998;41(3):525–33. https://doi.org/10.1016/ s0360-3016(98)00097-2.
  • Yoshioka Y, Suzuki O, Isohashi F, Seo Y, Okubo H, Yamaguchi H, et al. High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate cancer: clinical results for a median 8-year follow-up. Int J Radiat Oncol Biol Phys 2016;94(4):675–82. https://doi.org/10.1016/j.ijrobp.2015.05.044.
  • Yoshioka Y, Yoshida K, Yamazaki H, Nonomura N, Ogawa K. The emerging role of high dose-rate (HDR) brachytherapy as monotherapy for prostate cancer. J Radiat Res 2013;54(5):781-8. https://doi.org/10.1093/jrr/rrt027.
  • Yoshioka Y, Suzuki O, Otani Y, Yoshida K, Nose T, Ogawa K. High-dose-rate brachytherapy as monotherapy for prostate cancer: Technique, rationale and perspective. J Contemp Brachytherapy 2014;6(1):91-8. https://doi.org/10.5114/ jcb.2014.42026.
  • Demanes DJ, Ghilezan MI. High-dose-rate brachytherapy as monotherapy for prostate cancer. Brachytherapy 2014;13(6):529-41. https://doi.org/10.1016/ j.brachy.2014.03.002.
  • Yoshioka Y, Nose T, Yoshida K, Inoue T, Yamazaki H, Tanaka E, et al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: Treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 2000;48(3):675-81. https://doi.org/10.1016/ s0360-3016(00)00687-8.
  • Crook J, Marbán M, Batchelar D. HDR Prostate Brachytherapy. Sem Radiat Oncol 2020;30(1):49–60. https://doi.org/10.1016/j.semradonc.2019.08.00310.1016/ j.semradonc.2019.08.003.
  • Joiner MC, Kogel A, van der. Basic clinical radiobiology. 4th ed. CRC Press 2009; 392 p.
  • De Bari B, Daidone A, Alongi F. Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature. Crit Rev Oncol Hematol 2015;94(3):360-70. http://doi.org/10.1016/ j.critrevonc.2015.02.003.
  • Cosset J-M, Mornex F, Eschwège F. Hypofractionnement en radiothérapie: l’éternel retour. Cancer Radiother 2013;17(5–6):355–62. https://doi.org/10.1016/ j.canrad.2013.06.027.
  • Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation [low α/β value], similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002;52(1):6–13. https://doi.org/10.1016/S0360-3016(01)02664-5.
  • Переход от 2D брахитерапии к 3D брахитерапии с высокой мощностью дозы. Доклады МАГАТЭ по здоровью человека 2021;(12):1-54. [Электронный ресурс]. [Transition from 2D brachytherapy to 3D high dose rate brachytherapy. Doklady MAGATE po zdorov'yu cheloveka = IAEA Human Health Reports 2021;(12):1-54. [Electronic resource]. (In Russian)]. URL: https://www-pub.iaea.org/MTCD/Publications/PDF/P1681R_HHR12_web.pdf.
  • Strouthos I, Karagiannis E, Zamboglou N, Ferentinos K. High-dose-rate brachytherapy forprostate cancer: Rationale, current applications, and clinicaloutcome. Cancer Rep 2022;5(1):e1450. https://doi.org/10.1002/cnr2.1450.
  • NCCN Guidelines Version 1. 2023 Prostate Cancer. [Electronic resource]. URL: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
  • Morton G, McGuffin M, Chung HT, Tseng C-L, Helou J, Ravi A, et al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiother Oncol 2020;146:90–6. https://doi.org/10.1016/j.radonc.2020.02.009.
  • Strouthos I, Tselis N, Chatzikonstantinou G, Butt S, Baltas D, Bon D, et al. High dose rate brachytherapy as monotherapy for localised prostate cancer. Radiother Oncol 2018;126(2):270-77. https://doi.org/10.1016/j.radonc.2017.09.038.
  • Hoskin P, Rojas A, Ostler P, Hughes R, Alonzi R, Lowe G. Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. Radiother Oncol 2017;124(1):56-60. http://doi.org/10.1016/j.radonc.2017.06.014.
  • Krauss DJ, Ye H, Martinez AA, Mitchell B, Sebastian E, Limbacher A, et al. Favorable Preliminary outcomes for men with low- and intermediate-risk prostate cancer treated with 19 Gy single fraction high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2017;97(1):98-106. http://doi.org/10.1016/ j.ijrobp.2016.08.011.
  • Hauswald H, Kamrava MR, Fallon JM, Wang PC, Park SJ, Van T, et al. High-dose-rate monotherapy for localized prostate cancer: 10-year results. Int J Radiat Oncol Biol Phys 2016;94(4),667–74. http://doi.org/10.1016/j.ijrobp.2015.07.2290.
  • Jawad MS, Dilworth JT, Gustafson GS, Ye H, Wallace M, Martinez A, Chen PY, et al. Outcomes associated with 3 treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys 2016;94(4),657-66. http://doi.org/10.1016/j.ijrobp.2015.10.011.
  • Prada PJ, Jimenez I, Gonzalez-Suarez H, Fernandez J, Cuervo-Arango C, Mendez L. High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results. Brachytherapy 2012;11(2):105–10. doi:10.1016/j.brachy.2011.05.003.
  • Kukiełka AM, Dąbrowski T, Walasek T, Olchawa A, Kudzia R, Dybek D. High-dose-rate brachytherapy as a monotherapy for prostate cancer. Single-institution results of the extreme fractionation regimen. Brachytherapy 2015;14(3):359-65. https://doi.org/10.1016/j.brachy.2015.01.004.
  • Komiya A, Fujiuchi Y, Ito T, Morii A, Yasuda K, Watanabe A, et al. Early quality of life outcomes in patients with prostate cancer managed by high-dose-rate brachytherapy as monotherapy. Int J Urol 2013;20(2):185-92. https://doi.org/10.1111/j.1442-2042.2012.03125.x.
  • Hoskin P, Rojas A, Lowe G, Bryant L, Ostler P, Hughes R, et al. High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. Int J Radiat Oncol Biol Phys 2012;82(4):1376-84. https://doi.org/10.1016/j.ijrobp.2011.04.031.
  • Rogers CL, Alder SC, Rogers RL, Hopkins SA, Platt ML, Childs LC, et al. High dose brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol 2012;187(1):109-16. https://doi.org/10.1016/j.juro.2011.09.050.
  • Zamboglou N, Tselis N, Baltas D, Buhleier T, Martin T, Milickovic N, et al. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys 2013;85(3):672-8. https://doi.org/10.1016/j.ijrobp.2012.07.004.
  • Barkati M, Williams SG, Foroudi F, Tai KH, Chander S, van Dyk S, et al. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial. Int J Radiat Oncol Biol Phys 2012;82:1889–96. https://doi.org/10.1016/j.ijrobp.2010.09.006.
  • Demanes DJ, Martinez AA, Ghilezan M, Hill DR, Schour L, Brandt D, et al. High‐dose‐rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011;81(5):1286-92. https://doi.org/10.1016/j.ijrobp.2010.10.015.
  • Mark RJ, Anderson PJ, Akins RS, Nair M. Interstitial high‐dose‐rate brachytherapy as monotherapy for early stage prostate cancer: median 8‐year results in 301 patients. Brachytherapy 2010;9:S76. https://doi.org/10.1016/ j.brachy.2010.02.127
  • Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS. High‐dose‐rate prostate brachytherapy: an excellent accelerated‐hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 2010;33(5):481-8. https://doi.org/10.1097/COC.0b013e3181b9cd2f
  • Ghadjar P, Oesch SL, Rentsch CA, Isaak B, Cihoric N, Manser P, et al. Late toxicity and five year outcomes after high‐dose‐rate brachytherapy as a monotherapy for localized prostate cancer. Radiat Oncol 2014;9:122. https://doi.org/10.1186/1748-717X-9-122
  • Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004;171(3):1098‐104. https://doi.org/10.1097/01.ju.0000113299.34404.22.
  • Siddiqui ZA, Gustafson GS, Ye H, Martinez AA, Mitchell B, Sebastian E, et al. 5-year outcomes of a single institution prospective trial of 19 gy single-fraction HDR brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2019;104(5):1038-44. https://doi.org/10.1016/j.ijrobp.2019.02.010.
  • Tharmalingam H, Tsang Y, Ostler P, Wylie J, Bahl A, Lydon A, et al., Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localized prostate cancer: Early results of a UK national cohort study. Radiother Oncol 2020;143:95-100. https://doi.org/10.1016/j.radonc.2019.12.017.
  • Johansson B, Olsén JS, Karlsson L, Lundin E, Lennernäs B. High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer: long-term experience of Swedish single-center. J Contemp Brachy- therapy 2021;13(3):245–53. https://doi.org/10.5114/jcb.2021.105846.
  • Anderson EM, Kim S, Sandler HM, Kamrava M. High-dose-rate fractionated brachytherapy monotherapy for localized prostate cancer: a systematic review and meta-analysis. J Contemp Brachytherapy 2021;13(4):365-72. https://doi.org/10.5114/ jcb.2021.108590.
  • Hannoun-Levi JM, Chand-Fouche ME, Pace-Loscos T, Gautier M, Gal J, Schiappa R, et al. Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial. Clin Transl Radiat Oncol 2022;37:64-70. https://doi.org/10.1016/j.ctro.2022.08.007.
  • Henry A, Pieters BR, André Siebert F, Hoskin P. UROGEC group of GEC ESTRO with endorsement by the European Association of Urology. GEC-ESTRO ACROP prostate brachytherapy guidelines. Radiother Oncol 2022;167:244-51. https://doi.org/10.1016/j.radonc.2021.12.047.
Еще
Статья обзорная
SciUp 2024 © 2024 ©